- Home
- AIP vs GOSS Comparison
AIP vs GOSS Comparison
Compare AIP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- GOSS
- Stock Information
- Founded
- AIP 2003
- GOSS 2015
- Country
- AIP United States
- GOSS United States
- Employees
- AIP N/A
- GOSS N/A
- Industry
- AIP Semiconductors
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- AIP Technology
- GOSS Health Care
- Exchange
- AIP Nasdaq
- GOSS Nasdaq
- Market Cap
- AIP 244.1M
- GOSS 203.3M
- IPO Year
- AIP 2021
- GOSS 2019
- Fundamental
- Price
- AIP $7.25
- GOSS $1.11
- Analyst Decision
- AIP Strong Buy
- GOSS Strong Buy
- Analyst Count
- AIP 4
- GOSS 4
- Target Price
- AIP $12.75
- GOSS $7.50
- AVG Volume (30 Days)
- AIP 183.4K
- GOSS 1.5M
- Earning Date
- AIP 05-13-2025
- GOSS 05-20-2025
- Dividend Yield
- AIP N/A
- GOSS N/A
- EPS Growth
- AIP N/A
- GOSS N/A
- EPS
- AIP N/A
- GOSS N/A
- Revenue
- AIP $57,724,000.00
- GOSS $114,701,000.00
- Revenue This Year
- AIP $19.68
- GOSS N/A
- Revenue Next Year
- AIP $18.13
- GOSS $172.31
- P/E Ratio
- AIP N/A
- GOSS N/A
- Revenue Growth
- AIP 7.56
- GOSS N/A
- 52 Week Low
- AIP $5.46
- GOSS $0.50
- 52 Week High
- AIP $12.64
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- AIP 57.98
- GOSS 55.81
- Support Level
- AIP $6.64
- GOSS $1.06
- Resistance Level
- AIP $7.74
- GOSS $1.26
- Average True Range (ATR)
- AIP 0.36
- GOSS 0.11
- MACD
- AIP 0.17
- GOSS 0.03
- Stochastic Oscillator
- AIP 75.68
- GOSS 67.95
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.